Challenges and Opportunities in Achieving Bioequivalence for Fixed-Dose Combination Products
Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 3
Abstract
Fixed-dose combination (FDC) products are becoming a popular treatment option because of increased patient compliance and convenience, improved clinical effectiveness, and reduced cost to the patient, among several other reasons. A commonly applied approach for approval of a FDC product is demonstrating bioequivalence between the FDC and co-administration of individual mono-products, provided that there is adequate safety and efficacy data for co-administration of the individual agents. However, achieving bioequivalence between the FDC and individual mono-products can be very challenging, and sometimes not possible since combining multiple active ingredients, especially insoluble molecules, in a single drug product could complicate its biopharmaceutical and pharmacokinetic behavior. In this review, some of the major challenges often encountered while assessing bioequivalence during FDC development will be presented along with discussion of future opportunities to facilitate FDC development and approval.
Authors and Affiliations
Amitava Mitra, Yunhui Wu
Keywords
Related Articles
- EP ID EP681228
- DOI 10.1208/s12248-012-9378-x
- Views 57
- Downloads 0
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids
There are at least 2 types of cannabinoid receptor, CB1 and CB2, both G protein coupled. CB1 receptors are expressed predominantly at nerve terminals and mediate inhibition of transmitter release, whereas CB2 receptors a...
De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products
The online version of this article (doi:10.1208/s12248-015-9802-0) contains supplementary material, which is available to authorized users.
Statistical Considerations for Assessment of Bioanalytical Incurred Sample Reproducibility
Bioanalytical method validation is generally conducted using standards and quality control (QC) samples which are prepared to be as similar as possible to the study samples (incurred samples) which are to be analyzed. Ho...
Evaluation of USP apparatus 3 for dissolution testing of immediate-release products
We sought to evaluate whether U.S. Pharmacopeia (USP) apparatus 3 can be used as an alternative to USP apparatus 2 for dissolution testing of immediate-release (IR) dosage forms. Highly soluble drugs, metoprolol and rani...
Determination of carryover and contamination for mass spectrometry-based chromatographic assays
The Third American Association of Pharmaceutical Scientists/Food and Drug Administration Bioanalytical Workshop, held in 2006, reviewed and evaluated current practices and proposed that carryover and contamination be ass...